10/540979
JC17 Rec'd PCT/PTO 27 JUN 2005

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) The use of a complex nutritive base in an aqueous medium, the said base comprising at least a multiplicity of amino acids, vitamins, trace elements, and metallic salts and being free of any cellular growth factor or any biological extract of animal or cellular origin or any pharmaceutically active principle, as an ophthalmologic medicine or ophthalmic solution for application in external contact with the eye in man or in animals.

2. (Original) The use of a complex nutritive base in an aqueous medium, the said base comprising at least a multiplicity of amino acids, vitamins, trace elements, and metallic salts and being free of any cellular growth factor or any biological extract of animal or cellular origin or any pharmaceutically active principle, as a treatment product for the storage, preservation, transport, or placement of items or prostheses, such as contact lenses, which are designed to come into external contact with the cornea of the eye in man or in animals.

3. (Original) The use as claimed in claim 1, characterized in that the ophthalmologic medicine or ophthalmologic solution consists of a trophic composition in an aqueous medium comprising the complex nutritive base, an inhibitor of collagenases of the human or animal corneal epithelium, and a promoter of neocollagen synthesis.

4. (Original) The use as claimed in claim 2, characterized in that the treatment product consists of a trophic composition in an aqueous medium comprising the complex

nutritive base, an inhibitor of collagenases of the human or animal corneal epithelium, and a promoter of neocollagen synthesis.

5. (Currently Amended) The use as claimed in claim 3 ~~or 4~~, characterized in that the trophic composition is formulated so as to establish a pH between 7.3 and 7.5 and an osmolarity between 300 and 350 Osm.

6. (Original) The use as claimed in claim 5, characterized in that the inhibitor of collagenases is chosen from the group comprising cysteine, N-acetylcysteine, and EDTA calcium salt.

7. (Original) The use as claimed in claim 5, characterized in that the inhibitor of collagenases is N-acetylcysteine.

8. (Original) The use as claimed in claim 5, characterized in that the inhibitor of collagenases represents at most 5% and preferably between 0.05 and 0.5% by weight of the trophic composition.

9. (Original) The use as claimed in claim 5, characterized in that the promoter of neocollagen synthesis is proline or hydroxyproline.

10. (Original) The use as claimed in claim 5, characterized in that the promoter of neocollagen synthesis represents at most 0.5% and preferably 0.004% by weight of the trophic composition.

11. (Original) The use as claimed in claim 5, characterized in that it comprises hyaluronic acid and/or a salt of hyaluronic acid in a total proportion by weight of the trophic composition of at most 0.1% and preferably 0.07%.

12. (Original) The use as claimed in claim 5, characterized in that the trophic composition includes a preservative in a proportion by weight of the said composition of at most 0.0001%.

13. (Original) The use as claimed in claim 12, characterized in that the preservative is polyhexanide or polyhexamethylene biguanide.

14. (Original) The use as claimed in claim 12, characterized in that the trophic composition corresponds to the formula described by Table 2 in the description.

15. (Original) The use as claimed in claim 1, characterized in that the ophthalmologic medicine or ophthalmologic solution is in liquid form or in dry form, that is to say for reconstitution with an aqueous medium.

16. (Original) The use as claimed in claim 2, characterized in that the treatment product is in liquid form or in dry form, that is to say for reconstitution with an aqueous medium.

17. (Original) The use as claimed in claim 1, characterized in that the ophthalmologic medicine or ophthalmologic solution is in the form of drops or regenerating tears, or comfort drops, or eyewash, or solution.

18. (Original) The use as claimed in claim 1, characterized in that the ophthalmic solution is a comfort solution.

19. (New) The use as claimed in claim 4, characterized in that the trophic composition is formulated so as to establish a pH between 7.3 and 7.5 and an osmolarity between 300 and 350 Osm.